Key Takeaways
- Kodiak Sciences shares jumped about 141% after its drug Zenkuda met its primary endpoint in the pivotal Phase 3 DAYBREAK trial in wet AMD.
- Zenkuda’s edge is durability: it matched aflibercept on vision gains while 54% of its patients were on 6-month dosing under strict retreatment rules.
- Kodiak plans to file for approval in the fourth quarter of 2026, backed by five positive Phase 3 studies.
- Kodiak is still precommercial, so the next things to watch are FDA approval, how it funds a launch, and KSI-101’s Phase 3 data in December.
Kodiak Sciences (KOD) is up about 141% today. Before the open, the company said its lead eye drug, Zenkuda, passed its pivotal Phase 3 trial in wet AMD (age-related macular degeneration).
This is a huge deal – both for the company and its investors, and also for patients. Let’s dive in.
What exactly happened
The DAYBREAK study pitted Zenkuda against aflibercept, the drug Regeneron (REGN) sells as Eylea. The results:
- Zenkuda matched aflibercept on vision gains at year one, meeting its primary endpoint (p-value of 0.0007)
- 54% of Zenkuda patients were on 6-month dosing at year one
- A 0% intraocular inflammation rate(!), and a 0.5% cataract rate vs. 0.9% for aflibercept
Dr. David M. Brown, chief medical officer of Retina Consultants of America, summed it up:
“The DAYBREAK results with Zenkuda are truly impressive. Under an AI-guided retreatment algorithm that closely mirrors the zero-fluid-tolerance approach we use in clinic, more than half of patients were maintained on 24-week dosing through year one.”
Why durability is the whole game
These drugs are injected directly into the eye. Nobody wants more of those shots than necessary.
As Brown put it, “the holy grail remains the same: robust anatomic disease control and maximal visual gains, sustained with less frequent dosing.”
Here’s the thing: DAYBREAK’s rules were tough. Zenkuda patients got another shot for “any detectable fluid on OCT.” (That’s the retinal scan doctors use to spot disease activity.)
More than half of them still went six months between shots.
A huge outcome.
What’s next
Kodiak plans to file for approval in the fourth quarter. Its application will rest on five positive Phase 3 studies across wet AMD, diabetic retinopathy, and retinal vein occlusion.
That’s quite the comeback. “Four years and seven months after our first Phase 3 readout,” said chief medical officer J. Pablo Velazquez-Martin, “Zenkuda’s profile has come fully into focus.”
Of course, Kodiak is still precommercial. It needs FDA approval (which is never certain, although…I like its odds, and so does the market!), and then it has to pay for a launch against an entrenched standard of care. (And on vision gains, Zenkuda only matched aflibercept.)
And as you can see, cash is burning quickly:
I expect we’ll see management do a cash raise by diluting current shareholders ASAP.
That’s the price of playing the game in biotech – and if Zenkuda ends up doing anything like Eylea’s sales ($6 billion in 2024), then Kodiak has a lot of opportunity ahead of it – and looks cheap even after today’s pop.
The next test comes fast: Phase 3 data for KSI-101, in a different eye condition, in December.
So what’s Kodiak actually worth?
For now, it all depends on how big Zenkuda can get.
I like to use TIKR.com’s proprietary modeling tool, which requires just three inputs, to get a full financial model for what the stock could be worth in three years.
It’s simple, straightforward, and robust – using institutional-quality data…and you can build it for free.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!
